🇺🇸 FDA
Patent

US 9163022

Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors

granted A61KA61K31/519A61P

Quick answer

US patent 9163022 (Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors) held by VTV THERAPEUTICS LLC expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VTV THERAPEUTICS LLC
Grant date
Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/519, A61P, A61P1/00, A61P1/02